非小细胞肺癌(non-small cell lung cancer,NSCLC)作为全球范围内频发且极具侵袭性的癌症之一,传统的手术治疗、放化疗及靶向治疗等方法往往由于其固有的局限性,难以遏制病情的进展,导致预后效果并不理想.尽管近年来免疫治疗药物的出现为NSCLC治疗带来了新希望,显示出一定的治疗效果,但当前的疗效仍显不足,无法满足所有患者的治疗需求.因此积极探索新的免疫治疗手段来进一步降低患者的死亡率,已成为NSCLC研究领域的重要方向.本文旨在通过梳理和分析国内外相关文献,系统综述白细胞介素21(interleukin-21,IL-21)和滤泡辅助性T细胞(follicular helper T cells,Tfh)在NSCLC免疫治疗中的抗肿瘤作用,并探讨通过免疫治疗手段调控免疫检查点,以改善NSCLC治疗前景的可能性.
Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer
Non-small cell lung cancer(NSCLC)is a prevalent and aggressive global malignancy.Conventional sur-gical treatments,radiotherapy,chemotherapy,and targeted therapies often fall short in halting disease progression due to inher-ent limitations,resulting in suboptimal prognosis.Despite the advent of immunotherapy drugs offering new hope for NSCLC treatment,current efficacy remains insufficient to meet all patient needs.Therefore,actively exploring novel immunotherapeu-tic approaches to further reduce mortality rates in NSCLC patients has become a crucial focus of NSCLC research.This article aims to systematically review the anti-tumor effects ofinterleukin-21 and follicular helper T cells in NSCLC immunotherapy by summarizing and analyzing relevant literatures from both domestic and international sources,as well as exploring the potential for enhancing NSCLC treatment prospects through immune checkpoint regulation via immunotherapeutic means.
Lung neoplasmsFollicular helper T cellsInterleukin-21Immune checkpoint proteins
万方数据
维普
